Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Manitoba
$27,000.00
Characterization of IFN-Lambda Immunobiology in Control and Ulcerative Colitis Human Gut Tissue
EF 2025-26
Résumé
Ulcerative colitis (UC) is a chronic disease affecting over 100,000 Canadians, with worldwide incidence rising. UC is characterized by a dysregulated immune system leading to life-long inflammation and pain. Although medications for ulcerative colitis exist, their effectiveness varies among patients, they do not provide a cure, and thus new drug targets still need to be found.
Interferon lambda (IFN-L) is an immune protein which signals through a receptor made of IFN-LR1 and IFN-10RB. It is normally present to promote gut health and healing. Gut inflammation is much worse in mice without this protein. Much less is known for how IFN-L works in the human gut. Our lab has two new methods to study this; First, we have a new IFN-LR1 antibody that can help us detect where the receptor is found. Second, we can take human gut tissue and study how IFN-L affects the various cells in the lab when we can keep the tissue alive for 24 hours. We predict that IFN-L is unique because it not only helps the gut heal but can stop the immune cells that cause damage in UC.
In this project, I will study fresh gut tissue biopsies from healthy donors and UC patients (equal number of male and female samples). I will measure IFN-LR1 protein levels in tissue-resident immune cells and see if there are differences between disease state and gut site. I will also profile how IFN-L signals in gut cells across healthy and UC tissue by looking at gene and protein changes. My results will provide new data in our understanding of human IFN-L gut biology and if IFN-L could be a future drug to restore gut health and improve the life of those living with UC.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
573342
Name
Thapar Gunjan
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of IFN-Lambda Immunobiology in Control and Ulcerative Colitis Human Gut Tissue
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cytokines; Gastroenterology; Immunology; Inflammation; Inflammatory Bowel Disease; Interferon Lambda; Large Intestine; Signalling; Ulcerative Colitis
Abstract
Ulcerative colitis (UC) is a chronic disease affecting over 100,000 Canadians, with worldwide incidence rising. UC is characterized by a dysregulated immune system leading to life-long inflammation and pain. Although medications for ulcerative colitis exist, their effectiveness varies among patients, they do not provide a cure, and thus new drug targets still need to be found.
Interferon lambda (IFN-L) is an immune protein which signals through a receptor made of IFN-LR1 and IFN-10RB. It is normally present to promote gut health and healing. Gut inflammation is much worse in mice without this protein. Much less is known for how IFN-L works in the human gut. Our lab has two new methods to study this; First, we have a new IFN-LR1 antibody that can help us detect where the receptor is found. Second, we can take human gut tissue and study how IFN-L affects the various cells in the lab when we can keep the tissue alive for 24 hours. We predict that IFN-L is unique because it not only helps the gut heal but can stop the immune cells that cause damage in UC.
In this project, I will study fresh gut tissue biopsies from healthy donors and UC patients (equal number of male and female samples). I will measure IFN-LR1 protein levels in tissue-resident immune cells and see if there are differences between disease state and gut site. I will also profile how IFN-L signals in gut cells across healthy and UC tissue by looking at gene and protein changes. My results will provide new data in our understanding of human IFN-L gut biology and if IFN-L could be a future drug to restore gut health and improve the life of those living with UC.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Thapar, Gunjan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~